Skip to Main Content

Paper Details

Influence of background medical therapy on efficacy and safety of dapagliflozin in patients with heart failure with improved ejection fraction in the DELIVER trial.
Eur J Heart Fail
1
2023
Author NameAffiliation
Akshay S DesaiBrigham and Women's Hospital, Harvard Medical School
Mikhail KosiborodSaint Luke's Mid America Heart Institute, University of Missouri-Kansas City
Carolyn S P LamNational Heart Centre Singapore and Duke-National University of Singapore
Adrian F HernandezDuke University Medical Center
  • 1 - 4

Datasets

Release 1.2